BIOANALYTICAL METHOD DEVELOPMENT AND VALIDATION OF VILDAGLIPTIN A NOVEL DIPEPTIDYL PEPTIDASE IV INHIBITOR BY RP-HPLC METHOD
- Analytical Enantio-Separation of Linagliptin in Linagliptin and Metformin HC1 Dosage Forms by Applying Two-Level Factorial Design. Jadhav, Sushant B.; Mane, Rahul M.; Narayanan, Kalyanraman L.; Bhosale, Popatrao N. // Scientia Pharmaceutica;Oct-Dec2016, Vol. 84 Issue 4, p671
A novel, stability indicating, reverse phase high-performance liquid chromatography (RP-HPLC) method was developed to determine the S-isomer of linagliptin (LGP) in linagliptin and metformin hydrochloride (MET HC1) tablets (LGP-MET HC1) by implementing design of experiment (DoE), i.e.,...
- Simultaneous Determination of 11 Alkaloids in Crude and Wine-Processed Rhizoma Coptidis by HPLC-PAD. Ping Huang; Xiaocui Qian; Junsong Li; Xiaobing Cui; Lihua Chen; Baochang Cai; Shanzhong Tan // Journal of Chromatographic Science;Jan2015, Vol. 53 Issue 1, p73
A high-performance liquid chromatography method coupled with photo array diode detector has been developed and validated for simultaneous quantification of 11 active alkaloids in Rhizoma Coptidis (R.C.). The analysis was performed on a Benetnach-C18 column (250 Ã— 4.6 mm, i.d., 5 Î¼m) using...
- Outcomes trials indicate no cardiovascular risk for diabetes drug class. // Nature Reviews Drug Discovery;Oct2013, Vol. 12 Issue 10, p728
The article focuses on the report that the clinical trials of two dipeptidyl peptidase-4 inhibitors (DPP4) used to treat diabetes, such as saxagliptin and alogliptin, indicated that the two inhibitors are safe for the cardiovascular system.
- CLINICAL REVIEW. Saxagliptin: A dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes mellitus. Neumiller, Joshua J.; Campbell, R. Keith // American Journal of Health-System Pharmacy;9/15/2010, Vol. 67 Issue 18, p1515
Purpose. The pharmacology, pharmacokinetics, efficacy, safety, and dosage and administration of saxagliptin are reviewed. Summary. Saxagliptin is a selective, reversible inhibitor of dipeptidyl peptidase-4 (DPP-4) approved for the treatment of type 2 diabetes mellitus in adults. By inhibiting...
- First bite. Gorrell, Mark D. // Nature Structural Biology;Jan2003, Vol. 10 Issue 1, p3
Focuses on dipeptidyl peptidase IV (DPP-IV), a potential therapeutic target in treating type 2 diabetes. Indication of the multiplicity of function of DPP-IV; Immunological function of DPP-IV; Structure of DPP-IV; Components of the DPP-IV gene family.
- Which patients are candidates for dipeptidyl peptidase IV inhibitors? Marrs, Joel C.; Saseen, Joseph J. // American Journal of Health-System Pharmacy;6/15/2007, Vol. 64 Issue 12, p1261
The author reflects on the symptoms of the dipeptidyl peptidase IV (DPP4) inhibitors among the patients in the U.S. These inhibitors are considered as the latest class of medications which will be developed for the management of diabetes and are the first oral agents that target incretin...
- Vildagliptin: A novel oral therapy for type 2 diabetes mellitus. Lauster, Colleen D.; McKaveney, Teresa P.; Muench, Sarah V. // American Journal of Health-System Pharmacy;6/15/2007, Vol. 64 Issue 12, p1265
Purpose. The pharmacology, pharmacokinetics, clinical efficacy, adverse effects, drug interactions, and role in therapy of vildagliptin for the treatment of type 2 diabetes mellitus were reviewed. Summary. Vildagliptin is an agent in a new class of medications called dipeptidyl peptidase IV...
- To Understand the Effect of Physicochemical Parameter on Dipeptidyl Peptidase- IV (DPP-IV), Inhibitors by Quantitative Structure Activity Relationship (QSAR). Sourabh, Jain; Ram babu, Tripathi; Gaurav, Garg // Journal of Pharmacy Research;2012, Vol. 5 Issue 11, p5113
Diabetes mellitus is one of the most challenging chronic metabolic disorders around the world. About 366 million people have diabetes in 2011 and by 2030 this will have risen to 552 million, which caused around 4.6 million deaths in 2011. The number of people with Type-II diabetes is increasing...
- Paper of the month. // Pulse;Oct2013, p15
The article discusses the two placebo-controlled trials on the use of saxagliptin in type 2 diabetes patients at high risk of cardiovascular disease (CVD) and alogliptin in diabetics with acute coronary event, suggesting that gliptins do not affect CV outcomes.